Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
D-chiro-inositol is a naturally occurring stereoisomer of inositol, a cyclitol found in animal and plant cells. It is derived from myo-inositol through an insulin-dependent epimerization process. D-chiro-inositol acts primarily as an insulin sensitizer and plays a role in various signal transduction pathways, including those involving insulin and gonadotropins. Its mechanisms include enhancing insulin sensitivity, inhibiting aromatase transcription, and modulating the transdifferentiation between white adipose tissue and brown adipose tissue. These actions make it relevant for metabolic disorders such as polycystic ovary syndrome (PCOS), obesity, dysmetabolism (including type 2 diabetes mellitus), hypoestrogenic/hyperandrogenic disorders, and potentially bone health[1][5][6][8]. D-chiro-inositol is most commonly used as a dietary supplement rather than a pharmaceutical drug.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on d-chiro-inositol.